Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.16 USD | -16.99% | -19.11% | +35.61% |
07:39pm | Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says | MT |
05:37pm | Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.61% | 3.76B | |
-27.94% | 9.96B | |
-17.52% | 2.37B | |
-11.15% | 2.27B | |
-22.50% | 1.58B | |
+59.77% | 1.31B | |
-1.31% | 750M | |
+22.12% | 575M | |
-28.37% | 525M | |
+5.37% | 337M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating